lusutrombopag 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| thrombopoietin agonists | 5059 | 1110766-97-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a thrombopoietin receptor agonist
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 18, 2019 | EMA | SHIONOGI B.V. | |
| July 31, 2018 | FDA | SHIONOGI INC | |
| Sept. 28, 2015 | PMDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B02BX07 | BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Other systemic hemostatics |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Thrombocytopenic disorder | indication | 302215000 | DOID:1588 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.45 | acidic |
| pKa2 | 7.41 | acidic |
| pKa3 | 0.94 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 3MG | MULPLETA | SHIONOGI INC | N210923 | July 31, 2018 | RX | TABLET | ORAL | 7601746 | Sept. 5, 2024 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 3MG | MULPLETA | SHIONOGI INC | N210923 | July 31, 2018 | RX | TABLET | ORAL | July 31, 2023 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thrombopoietin receptor | Membrane receptor | AGONIST | EC50 | 7.08 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 6LL5JFU42F | UNII |
| D10476 | KEGG_DRUG |
| 4037779 | VANDF |
| C4309207 | UMLSCUI |
| CHEBI:136051 | CHEBI |
| CHEMBL2107831 | ChEMBL_ID |
| 49843517 | PUBCHEM_CID |
| DB13125 | DRUGBANK_ID |
| 9410 | INN_ID |
| C000611387 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10032 | IUPHAR_LIGAND_ID |
| 2054984 | RXNORM |
| 286900 | MMSL |
| 34734 | MMSL |
| d08854 | MMSL |
| 017667 | NDDF |
| 773263005 | SNOMEDCT_US |
| 773265003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Mulpleta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59630-551 | TABLET, FILM COATED | 3 mg | ORAL | NDA | 26 sections |